Cargando…
Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors
We describe a potential role for thymidine kinase-1, a general marker of cellular proliferation, to act as a prognostic biomarker in patients receiving CDK4/6 inhibitors for advanced hormone receptor-positive, HER2-negative breast cancer, with early data suggesting that it may also provide early ind...
Autores principales: | McCartney, Amelia, Malorni, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374612/ https://www.ncbi.nlm.nih.gov/pubmed/32382111 http://dx.doi.org/10.1038/s41416-020-0858-y |
Ejemplares similares
-
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019) -
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018) -
Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
por: Pfeiler, Georg, et al.
Publicado: (2022) -
Dubious Claims about Simplicity and Likelihood: Comment on Pinna and Conti (2019)
por: van der Helm, Peter A.
Publicado: (2020) -
Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509
por: Fusco, Vittorio, et al.
Publicado: (2021)